Sanofi just announced a recall for Auviq devices both 0.15 and 0.30 due to possible incorrect dosage administration.

Sanofi SA launches recall for Auviq devices both 0.15

-- On October 16, 2017, Aimmune entered into a clinical collaboration with Regeneron (REGN) and its strategic alliance collaborator Sanofi (SNY) to study AR101 treatment with adjunctive *dupilumab in peanut-allergic patients in a Phase 2 clinical trial.

Aimmune Therapeutics Inc. partnered with Sanofi Genzyme on Oct 16th 17'.

Eleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a company-wide rebranding.

Sanofi Genzyme acquired Sanofi Genzyme for $20.1B on Feb 3rd 22'.

In vitro diagnostic firm Sebia announced Tuesday it is partnering with Sanofi to develop a diagnostic test to mitigate possible interference from Sanofi's investigational antibody, isatuximab, in patients with multiple myeloma.

Sebia Group partnered with Sanofi Genzyme on Jan 14th 20'.

Regeneron and Sanofi developed Libtayo and partnered with Agilent for the use of PD-L1 IHC 22C3 pharmDx to evaluate PD-L1 expression in patients in the pivotal EMPOWER-Lung 1 clinical trial.

Sanofi Genzyme partners with Agilent Technologies, Inc.

Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic collaboration with Sanofi to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with challenging diseases in multiple therapeutic areas.

Nurix Therapeutics, Inc. partnered with Sanofi Genzyme on Jan 7th 21'.

Adagene, which is on a quest to produce immunotherapies that don’t attack healthy cells, is partnering with Sanofi for up to four “safe” antibody candidates in oncology.

Adagene Inc. partners with Sanofi Genzyme

Mr. Pucci joined Sanofi in 2009 as Executive Vice President and Head of Human Resources, and has substantially transformed the human resources function and supported Sanofi through a period that saw considerable change in the company.

Sanofi Genzyme hired Pucci as Executive Vice President and Head of Human Resources on Jan 1st 09'.

Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1 st Paris - July 26, 2018 - Roberto Pucci, Head of Human Resources, will retire from Sanofi after more than 9 years of service with the company.

Roberto Pucci retires from Sanofi Genzyme

Parisian AI biotech startup Owkin has received a $180 million investment from multi-national pharmaceutical giant Sanofi.

Sanofi Genzyme invests into Owkin Inc in $180M

French pharmaceutical company Sanofi struck a $30 million, five-year agreement with digital health company DarioHealth.

DarioHealth Corp partners with Sanofi Genzyme

DarioHealth's deal with Sanofi will see the companies working together to develop digital health solutions for Dario's platform.

Sanofi Genzyme is developing digital health solutions for Dario's platform

Under the terms of the five-year deal, Sanofi digital health apps will be integrated into Dario’s platform and Sanofi’s sales muscle will be deployed to market the combined offering.

Sanofi Genzyme integrates with DarioHealth Corp

BARDA and Sanofi Pasteur, the vaccines global business unit of Sanofi, are expanding their collaboration to develop a SARS-CoV-2 vaccine.

Sanofi Genzyme is developing SARS-CoV-2 vaccine

Throughout its history, the company has experienced a number of transformations, the latest of which was in 2009, when Sanofi merged with Aventis.

Sanofi Genzyme merged with Aventis on Jan 1st 09'.

While Blackstone has provided some financing to support the studies, Sanofi partnered with Enable Injections, a drug delivery technology company for subcutaneous formulation delivery.

Sanofi Genzyme partners with Enable Injections Inc.

Sanofi will continue to fully manage the clinical programme and retain full rights and control of Sarclisa.

Sanofi Genzyme is developing clinical programme and retain full rights and control of Sarclisa

Sanofi ( SNY ) was advancing by more than 2% after saying it is partnering with Blackstone ( BX ) to boost the clinical development of Sarclisa, a treatment for multiple myeloma.

Sanofi Genzyme partners with The Blackstone Group

Having first teamed up with Immunogen almost 20 years ago, Sanofi has now joined forces with Seagen to jointly fund and develop three anti-cancer ADCs.

Sanofi Genzyme partnered with Seagen Inc. on Mar 16th 22'.

Sanofi had previously planned to list the business via an initial public offering, but is now pursuing a spinoff.

Sanofi Genzyme goes public

Sanofi ranked No. 27 on The DiversityInc Top 50 Companies for Diversity list in 2021.

Sanofi Genzyme recognized as No. 27 on The DiversityInc Top 50 Companies for Diversity list in 2021

SAN FRANCISCO, March 22, 2022--Prellis Biologics has entered into a collaboration and license option agreement with Sanofi.

Prellis Biologics partnered with Sanofi Genzyme on Mar 22nd 22'.

Get the information you need In addition to information available from NNPDF, Sanofi also recently launched a new website called ASMDFacts.com with information for both patients and clinicians.

Sanofi Genzyme launched ASMDFacts on Feb 12th 22'.

According to Bloomberg, Sanofi will invest the funds over the next several years to build out its mRNA facilities and programs.

Sanofi Genzyme invests into assets : mRNA facilities

In recognition of its ongoing support and partnership, AMGA has named Sanofi as the recipient of its 2022 Distinguished Corporate Partner Award.

Sanofi Genzyme receives award 2022 Distinguished Corporate Partner Award

Lately in 2019, Sanofi and Aetion launched enterprise-wide collaboration to advance regulatory submissions using real-world evidence.

Sanofi Genzyme launched enterprise-wide collaboration to advance regulatory submissions on Jan 1st 19'.

In 2021, Sanofi announced several critical steps in this journey with the unveiling of the creation of EUROAPI and the appointment of Karl Rotthier as its CEO in January, the appointment of Viviane Monges as Chair of the Supervisory Board in July and the finalization of the carve-out in December 2021.

Sanofi Genzyme hired Viviane Monges as Chair of the Supervisory Board on Jan 1st 21'.

ATS’s corporate sponsors also include vaccine giant Merck, CSL Behring, which partnered AstraZeneca to produce its COVID-19 vaccine, and Novartis, which like Sanofi partnered with Pfizer to produce its COVID-19 vaccine.

Sanofi Genzyme is developing COVID-19 vaccine

Sanofi and Seagen announced on March 16, 2022, an exclusive collaboration agreement to design, develop, and commercialize novel antibody-drug conjugates (ADCs).

Sanofi Genzyme is developing novel antibody-drug conjugates on Mar 16th 22'.

Hudson joined Sanofi at the start of September after previously serving as Novartis’ pharmaceuticals president.

Sanofi Genzyme hires Hudson as pharmaceuticals president

Orange has joined forces with Sanofi, Capgemini and Generali to launch Future4care, a start-up accelerator which aims to facilitate the rapid deployment of e-health solutions and their availability on the market.

Orange Group partners with Sanofi Genzyme

Science 37 has partnered with big names in pharma, such as Sanofi and Novartis, and remains one of the major players in the virtual trial space.

Science 37, Inc. partners with Sanofi Genzyme

Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences in the field of treatments for oncology, immunology and inflammation.

Sanofi Genzyme partnered with IGM Biosciences, Inc. on Mar 29th 22'.

This allowed Sanofi expanded to not only expand its vaccine portfolio but expand its U.S. presence by leveraging non-egg-based manufacturing technologies.

Sanofi Genzyme expands offices in United States

Two weeks ago, Sanofi partnered with SeaGen to make antibody-drug conjugates, a type of tumor-targeting medicine that has been the at the center of several industry deals in recent years.

Sanofi Genzyme partnered with Seagen on Mar 15th 22'.

Since COVID-19 made it almost impossible for families to hold face-to-face consults with medical experts, Sanofi launched “FAMhealthy,” a series of webinars where families could get medical tips and advice.

Sanofi Genzyme launches FAMhealthy

Sanofi and IGM announce partnership to develop IgM antibody agonists against oncology and immunology/inflammation targets.

Sanofi Genzyme is developing IgM antibody agonists against oncology

– For instance, in April 2018, Servier acquired Shire's oncology business to gain direct commercial access in the U.S. – Additionally, in January 2018, Sanofi announced its plan to acquire ELOCTATE.

Sanofi Genzyme acquires Eloctate

Indie Bio is delighted to work in collaboration with Sanofi in novel antibody research with its differentiated approach.”

Indie Bio partners with Sanofi Genzyme

Two are already on the market, from Amgen and Regeneron, partnered with Sanofi.

Amgen Foundation, Inc. partners with Sanofi Genzyme

Sanofi is investing up to $60 million in a UK based gene therapy start up, Gyroscope Therapeutics.

Sanofi Genzyme invests into Gyroscopetx in $60M

Sanofi launches today its Diversity, Equity & Inclusion (DE & I) Board, the first -of-its-kind in the pharmaceutical industry to feature outside advisors.

Sanofi Genzyme launched Diversity, Equity & Inclusion Board on Apr 4th 22'.

Sanofi launched its DE&I iniative in June 2021, when it set a target date of 2025 to have what it called “representative leadership.”

Sanofi Genzyme launches DE&I iniative

Sanofi and Regeneron, marketer of asthma heavy hitter Dupixent, is working on an anti-IL-33 antibody, itepekimab, for COPD.

Sanofi Genzyme is developing anti-IL-33 antibody, itepekimab

For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, for investigating KN026 in combination with other drugs for the treatment of HER2 breast cancer.

Alphamabonc partnered with Sanofi Genzyme on Jun 1st 20'.

In a New York State filing, Sanofi says it's laying off 25 Kadmon employees as it closes the site at 450 East 29th in New York City.

Sanofi Genzyme decreases headcount by 25

A more immediate threat: Sanofi and Regeneron introduced Dupixent, an IL-4 and IL-13 blocker, for the treatment of more severe eczema cases in March.

Sanofi Genzyme launched Dupixent on Mar 1st 17'.

Sanofi will pay IGM Biosciences $150 million and potentially billions more in milestone payments as part of a deal to develop agonist antibodies for cancer and inflammatory diseases.

Sanofi Genzyme is developing agonist antibodies for cancer and inflammatory diseases

Sanofi plans an initial public offering for the firm on the Euronext Paris stock exchange by 2022.

Sanofi Genzyme went public on Jan 1st 22'.

In March, Paris-based Voluntis expanded its partnership with Sanofi to run pilot programs based on the Insulia platform in North America and Europe.

Voluntis partnered with Sanofi Genzyme on Mar 1st 17'.

In 2021, the healthcare company Sanofi launched its mRNA Centre of Excellence.

Sanofi Genzyme launched mRNA Centre of Excellence on Jan 1st 21'.

In 2019, Sanofi partnered with Happify Health to produce a DTx app to improve mental health in patients with multiple sclerosis.

Sanofi Genzyme is developing DTx app to improve mental health in patients with multiple sclerosis on Jan 1st 19'.

In January 2021, French drug company Sanofi joined the partnership and agreed to manufacture 125 million doses, despite being a direct competitor of BioNTech.

Sanofi Genzyme identified as competitor of Biontech on Jan 1st 21'.

Also at ADA, Sanofi unveiled its own hypoglycemia study on Toujeo, based on real-world evidence gleaned on that drug, plus two Novo Nordisk basal insulins and Sanofi’s Lantus.

Sanofi Genzyme launches hypoglycemia study on Toujeo

Genzyme, which was later bought by Sanofi, sought a refund of $5 million in franchise taxes it paid from 2004 to 2010.

Sanofi Genzyme acquired Genzyme for $5M on Apr 14th 22'.

After collaborating with Translate Bio on an mRNA platform in 2018, Sanofi purchased the company for $3.2 billion last year and established a first-of-its-kind mRNA Center of Excellence.

Sanofi Genzyme invests into assets : mRNA Center of Excellence in the amount of $3.2B

The French pharma has partnered with the Formula One racing team to boost "efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing,” Sanofi said Tuesday.

Sanofi Genzyme partnered with Formula 1 on Apr 26th 22'.

Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company’s ambition to attain world-class standards of manufacturing excellence.

Sanofi Genzyme partnered with McLaren Automotive on Apr 28th 22'.

Glaxo is also developing a separate Covid vaccine with French drugmaker Sanofi.

Sanofi Genzyme is developing Covid vaccine

DE) and Sanofi(SASY.PA) have announced plans to invest in production sites in Singapore.

Sanofi Genzyme will expand facilities to Singapore, Singapore on Jun 1st 22'.

US biotech Terran Biosciences, which is focussed on therapeutics for neurological and psychiatric diseases, has entered into an agreement with French pharma major Sanofi (Euronext: SAN) for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.

Terranbiosciences partners with Sanofi Genzyme

AstraZeneca has also teamed up with Sanofi in the hopes of producing a vaccine, which would help the company recoup lost revenue.

AstraZeneca plc partners with Sanofi Genzyme

In addition to this, Mirati Therapeutics also announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib with Sanofi's investigational SHP2 inhibitor SAR442720 (RMC-4630).

Mirati Therapeutics, Inc. partners with Sanofi Genzyme

2 SAR443820, previously known as DNL788, was developed by scientists at Denali Therapeutics, which entered into a partnership with Sanofi to develop and commercialize the class of therapies in late 2018.

Denali Therapeutics Inc. partners with Sanofi Genzyme

Sanofi is investing €900 million (S$1.3 billion) over five years to create two such facilities globally – one in France and the $638 million production site in Tuas, Singapore, which will allow it to quickly pivot to making new vaccines that might be needed to combat future pandemics.

Sanofi Genzyme invests into assets : production site in the amount of $1.3B

Sanofi sued Merck for patent infringement last September, triggering an automatic 30-month stay under the Hatch-Waxman Act, which governs generic drugs’ path to market.

Sanofi Genzyme filed suit against Merck on Sep 1st 16'.

In February 2021, SIRION Biotech GmbH, has signed a license and collaboration agreement with Sanofi, to develop improved tissue-selective adeno-associated virus (AAV).

Sanofi Genzyme is developing improved tissue-selective adeno-associated virus on Feb 1st 21'.

Penn State Lehigh Valley received a $10,000 grant from Sanofi in December to support its Student Emergency Fund and LionShare Food Pantry.

Sanofi Genzyme invested into Psulvalumni in $10K on Dec 1st 21'.

Sanofi has launched a pioneering funding spin-out called Foundation S. Using donations, partnerships and collective action, the project will concentrate on three critical areas – childhood cancer, the health of communities that are most vulnerable to climate change and access to life-saving treatment.

Sanofi Genzyme launches Foundation S. Using donations

In addition to the vaccines, Sanofi and AstraZeneca are working on an antibody therapy that could vaccinate newborns to prevent RSV disease.

Sanofi Genzyme is developing antibody therapy that could vaccinate newborns to prevent RSV disease

“ALS is a devastating neurodegenerative disease for which effective treatment options are a critical unmet medical need,” Nazem Atassi, MD, the global head of early neurology development at Sanofi, said in a press release.

Nazem Atassi leaves Sanofi Genzyme as global head of early neurology development

Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields.

Kymera Body Board, LLC partners with Sanofi Genzyme

Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

Sanofi Genzyme hired Zerhouni as scientific advisor to the Chief Executive Officer on Jan 1st 09'.

Key Highlights From The Report In February 2019, Sanofi entered into a definitive agreement with NH TherAGuIX for the introduction of AGuIX ® Nanoparticle in the field of cancer treatment.

Sanofi Genzyme partnered with Nhtheraguix on Feb 1st 19'.

In December 2016, Pfizer launched an app in order to support patients with depression.The New York health system announced that it will be partnering with Sanofi and digital health company Sema4 on the remote monitoring program.

Pfizer, Inc. partnered with Sanofi Genzyme on Dec 1st 16'.

McDermott joins Rafael from Sanofi, where she served as Vice President of Human Resources.

McDermott leaves Sanofi Genzyme as Vice President of Human Resources

And in the U.S., Sanofi is working on Achieve Control, which will investigate patients naïve to insulin who are randomized to receive either Toujeo or a comparator.

Sanofi Genzyme is developing Achieve Control

Sanofi was developing its own MS drug, Aubagio (teriflunomide), at the time.

Sanofi Genzyme is developing Aubagio

Biond's clinical I-O program, BND-22 (SAR444881), is an Ig-Like Transcript 2 (ILT2) receptor-blocking antibody that was partnered with Sanofi.

Biond Biologics partnered with Sanofi Genzyme on Jan 1st 21'.

Sanofi on Wednesday unveiled a new subscription model to allow diabetes patients access to its insulins.

Sanofi Genzyme launched subscription model to allow diabetes patients access to insulins on Apr 10th 19'.

9 Recognizing this need, Sanofi Consumer Healthcare has launched Zantac 360°™, formulated with famotidine, available as of spring 2021.

Sanofi Genzyme launched Zantac 360° on Jun 23rd 21'.

The company entered an exclusive global licence agreement with Sanofi in January last year to develop and market BND-22.

Sanofi Genzyme is developing BND-22 on Jan 1st 22'.

On March 31, 2022, Sanofi published the Information Statement attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Sanofi Genzyme launched Exhibit 99.1 on Mar 31st 22'.

EUROAPI has expanded a collaboration with Sanofi, which will see it support Sanofi's mRNA vaccine platform with the development of lipid nanoparticles.

Apple Inc. partners with Sanofi Genzyme

Rallybio, a New Haven biotech, has acquired from Sanofi worldwide exclusive rights to develop a drug candidate designed to treat patients with severe anemia from certain blood disorders.

Sanofi Genzyme sells assets to Rallybio LLC

Similarly, in November 2021, Sanofi has partnered with MyoKardia, both in partnership will develop and discover targeted therapeutics to treat patients with genetic heart disease.

Sanofi Genzyme partnered with MyoKardia Inc. on Nov 1st 21'.

Sanofi acquired the licensing to sell Cialis as an over-the-counter treatment years ago from Eli Lilly.

Sanofi Genzyme acquired Cialis on Jun 1st 21'.

(Bloomberg) -- Regeneron Pharmaceuticals Inc. agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1 billion, revisiting a deal that helped the French company re-enter the field of cancer research.

Sanofi Genzyme sells assets to Regeneron in the amount of $1.1B

When Sanofi launched its “16 Vaccine” campaign several years ago, it wanted to address the lag in meningitis booster shots that was happening around age 16.

Sanofi Genzyme launched 16 Vaccine on Jun 1st 21'.

Sanofi today launches Action 2022, its global employee share ownership plan, open to 86 000 employees in 59 countries.

Sanofi Genzyme launched Action 2022 on Jun 3rd 22'.

Sanofi announces the launch of its first Digital Accelerator to foster its ambition to become a leading digital healthcare company.

Sanofi Genzyme launches Digital Accelerator

Sanofi announced a huge $5.3 billion collaboration with Exscientia in drug discovery, while Thermo Fisher Scientific announced it was partnering with Medidata Acorn AI to optimize clinical trials.

Sanofi Genzyme partners with Medidata Solutions

Genzyme, headquartered in Cambridge, was sold to French drugmaker Sanofi-Aventis in 2011 for about $20 billion.

Sanofi-Aventis (Maroc) acquired Sanofi Genzyme for $20B on Jan 1st 11'.

Sanofi Consumer Healthcare has teamed up with digital health player Cara Care to offer an innovative treatment for IBS which goes beyond the pill and helps sufferers access personalized support for their illness.

Sanofi Genzyme partners with Cara Care

In a collaboration, Sanofi and Sobi are working to develop BIVV001 (efanesoctocog alfa) and fulfill an unmet need for patients with hemophilia A. Now, the collaboration has proven fruitful, as the FDA gave the drug Breakthrough Therapy Designation for this indication.

Sanofi Genzyme is developing BIVV001 and fulfill an unmet need for patients with hemophilia A. Now

When it launched Dengvaxia, Sanofi said the first-to-market vaccine had the potential to become a $1 billion product.

Sanofi Genzyme launches Dengvaxia

… Immunocore (NASDAQ: IMCR), which has offices in Conshohocken; Rockville, Maryland; and Oxfordshire, England, has entered into a clinical trial collaboration and supply agreement with Sanofi.

Immunocore Ltd partners with Sanofi Genzyme

Sanofi is fac­ing down a strike threat in Ko­rea amid an in­creas­ing num­ber of con­fronta­tions be­tween Big Phar­ma and their la­bor unions over pay de­mands.

Sanofi Genzyme has issues with strike threat

Additionally, Sanofi is partnering with Women in Tech® to close the gender gap in the digital health field.

USA - Data Scientist II (Clinical) (contract)

Location

Salary Estimate

Seniority

Tech stacks

About Sanofi

Unlock all Arc benefits!